Ownership
Public
Employees
~50
Therapeutic Areas
Oncology
Stage
Phase 2
Modalities
Small molecule

Cyteir Therapeutics General Information

Lead compound CYT-0851 is in Phase 1/2 trials for hematologic cancers and solid tumors. Company ceased operations in 2024.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Lexington, Massachusetts
United States

Drug Pipeline

CYT-0851
Phase 1/2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Cyteir Therapeutics's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Cyteir Therapeutics Funding

Deal TypeDateAmountStatusStage
Later Stage VCFeb 11, 2021$80.0MCompletedPhase 2
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Cyteir Therapeutics's complete valuation and funding history, request access »